Pharmafile Logo
Pharmafocus logo
Advanced Search

Sutent

Showing 15 posts of 19 posts found.

merck-keytruda

Keytruda/Inlyta combo scores FDA approval in advanced kidney cancer

April 23, 2019
Manufacturing and Production, Sales and Marketing FDA, MSD, Pfizer, Sutent, inlyta, keytruda, pharma

MSD’s anti-PD-1 therapy Keytruda (pembrolizumab) has secured another approval from the FDA, this time as a first-line treatment in combination …

News
pfizer-building-logo1web

FDA expands use of Pfizer’s Sutent in kidney cancer

November 17, 2017
Medical Communications, Sales and Marketing Cancer, Kidney cancer, Pfizer, Sutent, pharma

Pfizer has announced that the FDA has expanded the use of its tyrosine kinase inhibitor Sutent (sunitinib malate) to include …

News
exelixis_hq_web

Exelixis’ Cabometyx smashes Pfizer cancer drug in Phase II trial

October 11, 2016
Manufacturing and Production, Research and Development Cabometyx, Exelixis, Pfizer, Phase II, Sutent, advanced renal cell carcinoma

Phase II results presented by genomics-based discovery company  Exelixis at the European Society for Medical Oncology (ESMO) congresss has put …

News
Inlyta image

NICE backs Pfizer’s drug for advanced kidney cancer

December 16, 2014
Sales and Marketing NICE, Pfizer, Sutent, Votrient, Zytiga, axitinib, inlyta, xofigo

UK healthcare guidance body NICE has issued final draft guidance recommending Pfizer’s Inlyta for advanced kidney cancer. The draft recommendation …

News
Pfizer New York HQ

Pfizer revenue drops, but new cancer drugs shine

July 29, 2014
Research and Development, Sales and Marketing Cancer, Inlyta. axitinib, Lipitor, Lyrica, Pfizer, Q2, Sutent, viagra

Pfizer saw a 2% drop in sales for the second quarter but has pointed to the stellar growth of its …

News
Votrient image

‘More patients want Votrient’

April 2, 2014
Research and Development, Sales and Marketing Cancer, GSK, Pfizer, Sutent, Votrient

GlaxoSmithKline is looking at patient satisfaction as a potential marketing tool for its kidney cancer drug Votrient, setting up a …

News
Pfizer image

SMC approves Inlyta

November 13, 2013
Sales and Marketing Pfizer, SMC, Sutent, inylta, rcc

Pfizer’s kidney cancer drug Inlyta has been approved by the drugs watchdog in Scotland, making it the only country in …

News
votrient image

Survival boost for Votrient in mRCC

October 2, 2012
Research and Development, Sales and Marketing GSK, Nexavar, Pfizer, Sutent, Votrient

GlaxoSmithKline’s renal cell carcinoma drug Votrient has proved itself non-inferior to a bitter rival, Pfizer’s Sutent, in terms of progression-free …

News
Pfizer image

Torisel-Avastin combo fails in kidney cancer

August 13, 2012
Research and Development, Sales and Marketing R&D, Sutent, Torisel, avastin, failure, rcc

Combining Pfizer’s Torisel and Roche’s Avastin does not increase survival rates for advanced kidney cancer patients. This is according to …

News

Pfizer’s Inlyta gains European recommendation

May 28, 2012
Sales and Marketing Inlyta. axitinib, Sutent, renal cell carcinoma

Pfizer’s kidney cancer pill Inlyta has been recommended for use by a European committee. The Committee for Medicinal Products for …

News

FDA approves Pfizer cancer drug Inlyta

January 30, 2012
Sales and Marketing Nexavar, Pfizer, Sutent, rcc, renal cell carcinoma

Pfizer’s kidney cancer drug Inlyta has gained US approval for second line treatment for the disease. Inlyta (axitinib) is now …

News

The renal cell carcinoma market: Votrient to challenge Sutent’s lead

November 25, 2010
Sales and Marketing GSK, GlaxoSmithKline, Pfizer, Sutent, Votrient, rcc, renal cell carcinoma

After decades of no new medicines emerging to treat renal cell carcinoma, no fewer than five new drugs were approved …

Feature

Sutent disappoints in lung cancer

August 24, 2010
Research and Development, Sales and Marketing NSCLC, Pfizer, Sutent, Tarceva

Pfizer’s Sutent has failed to improve overall survival in lung cancer patients when combined with Roche’s Tarceva. Pfizer’s SUN 1087 …

News

NICE responds to Daily Mail cancer drug claims

April 12, 2010
Sales and Marketing NICE, Sutent, election, off label

NICE has responded to a Daily Mail article on access to cancer drugs, in order to clear up claims of …

News

Pfizer suffers late-stage cancer drug failures

March 12, 2010
Research and Development Cancer, Pfizer, Sutent, figitumumab

Pfizer has suffered late-stage trial failures for Sutent and lung cancer candidate figitumumab. Kidney cancer drug Sutent (sunitinib) failed to …

News

Latest content

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024

AskBio initiates phase 2 Parkinson’s trial recruitment

June 26, 2024

AstraZeneca’s Tagrisso approved in Japan for lung cancer treatment

June 25, 2024

ILiAD Biotechnologies announces collaboration with Emmes Group on phase 3 pertussis vaccine trial

June 25, 2024

GSK’s Jemperli accepted for review by EMA for endometrial cancer treatment

June 24, 2024